

**Eurocor GmbH today announced the launch of the DIOROCT Trial
with PI Prof. Patrick W. Serruys
DIOR® Drug-Eluting Balloon integrated in prospective, multicenter,
randomized trial for de novo lesions**

Bonn, Germany | Bengaluru, India | May 2, 2011

Opto Circuits (India) Ltd's subsidiary Eurocor today announced the launch of the new DIOROCT trial. The international DIOROCT trial is a prospective, multicentre, randomized trial which will include up to 100 patients with stable angina pectoris and 1 de novo lesions in a native coronary artery. The Principal Investigator for this trial is Prof. Patrick W. Serruys, Erasmus Hospital Rotterdam.

The three arm trial is comparing the OCT outcome at four months on Eurocor's 2nd Generation Drug-Eluting Balloon (DEB) DIOR® vs. Bare Metal Stent (BMS) + DEB vs. BMS.

"The primary objective of this trial is to investigate if adjunctive use of the Paclitaxel-eluting balloon DIOR® after stenting with BMS may provide significant benefits on lumen area, comparable to those obtained with BMS only. The expectation that stent struts are fully covered after 4 months while maintaining low restenosis rate by the short application of the Paclitaxel-eluting balloon has potential tremendous clinical benefit", says Dr. Robert Jan van Geuns, interventional cardiologist and lead investigator (member of the steering committee).

"This is another big step for Eurocor to show the competence of our high-class products. We are happy to have the DIOR® DEB involved in this superior study", says Katja Hausner, Director Corporate Business Affairs at Eurocor.

About: DIOR®

DIOR® is a patent-pending drug (paclitaxel) -eluting breakthrough balloon dilatation catheter developed by scientists at Eurocor and used by hundreds of interventional cardiologists across the world. It can be effectively used in patients with in-stent restenosis, bifurcation lesions and lesions in small vessels. More information available at:

http://www.eurocor.de/products/dior/product_information/

About: Eurocor GmbH

Eurocor GmbH is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor is providing interventional cardiologists with innovative, coronary stent technologies and special cardiovascular and endovascular devices. The products manufactured by the company in Bonn are used in minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Strong research and development, close collaboration with clinicians, outstanding

Eurocor GmbH: Rheinwerkallee 2, D-53227, Bonn | +49 - 228 / 20 150 - 0

Opto Circuits (India) Ltd.: Plot 83, Electronics City, Hosur Road, Bengaluru 560 100 | +91 80 2852 1040/41/42

quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for the delivery of drugs via a balloon catheter that is particularly compatible to the patient. Eurocor GmbH is an Opto Circuits (India) Ltd. Company. For more information, please visit www.eurocor.de and www.optoindia.com.

About: Opto Circuits (India) Ltd

Opto Circuits (India) Ltd. (OCI) is an MNC in the business of design, development, manufacture and marketing of healthcare equipment and medical interventional products. The product profile includes USFDA-listed, CE-marked cardiac and vital signs monitoring systems, anesthesia and respiratory care equipment, automated external defibrillators, stents, catheters, body implants and consumables. Some of OCI's well-known brands are Cardiac Science, Criticare, Eurocor, Ormed, Mediaid and Unetixs. The company's key markets are North America, Europe and BRIC countries.

Contact

Eurocor GmbH
Claudia Tischendorf
Phone: +49 (0) 228 201 50 26
E: pressoffice@eurocor.de

Opto Circuits (India) Ltd.
Phone: +91 80 2852 8088
E: Media - media@optoindia.com;
Investors: ir@optoindia.com